IP Library › Granted Patent US 12,653,881
Granted Patent B2
US 12,653,881 · App. 18/010,294 · Granted Jun 16, 2026

Measles virus vaccine expressing SARS-CoV-2 protein(s)

Inventors: William Paul Duprex (Pennsylvania, PA); Natasha Tilston-Lunel (Pittsburgh, PA); Shamkumar Nambulli (Bridgeville, PA); Linda J. Murphy (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
A61K39/215A61K39/165A61P31/14C07K14/005C12N7/00C12N15/86A61K2039/5256A61K2039/53A61K2039/575C12N2760/18434C12N2760/18443C12N2770/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,881
App. No.
18/010,294
Granted
Jun 16, 2026
Kind
B2
Abstract

A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.

Claims (20)

1 . A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, wherein the vector is a recombinant Edmonston-Zagreb (EZ) measles viral vector.

2 . The recombinant measles viral vector of claim 1 , wherein the nucleic acid sequence has been codon optimized.

3 . The recombinant measles viral vector of claim 1 , wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-COV-2 spike glycoprotein.

4 . The recombinant measles viral vector of claim 3 , wherein the ER retention sequence of the SARS-COV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail.

5 . The recombinant measles viral vector of claim 2 , wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-COV-2 spike glycoprotein.

6 . The recombinant measles viral vector of claim 5 , wherein the ER retention sequence of the SARS-COV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail.

7 . The recombinant measles viral vector of claim 1 , wherein the nucleic acid sequence encoding the SARS-COV-2 spike glycoprotein is selected from the group consisting of SEQ ID NO: 1 (S6), SEQ ID NO: 2 (S-CO), SEQ ID NO: 3 (S-CO-AA), SEQ ID NO: 4 (S), SEQ ID NO: 5 (S-CO-AA-PP), SEQ ID NO: 6 (S-CO-AA-fneg-PP), and SEQ ID NO: 7 (S-CO-AA-fneg).

8 . The recombinant measles viral vector of claim 1 , wherein the amino acid sequence of the SARS-CoV-2 spike glycoprotein is selected from the group consisting of SEQ ID NO: 8 (S6), SEQ ID NO: 9 (S-CO), SEQ ID NO: 10 (S-CO-AA), SEQ ID NO: 11 (CoV2-S), SEQ ID NO: 12 (S-CO-AA-PP), SEQ ID NO: 13 (CO-AA-fneg-PP), and SEQ ID NO: 14 (S-CO-AA-fneg).

9 . The recombinant measles viral vector of claim 1 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 15 (pSARS-CoV2-S6), SEQ ID NO: 16 (SARS-CoV-2-S-CO), SEQ ID NO: 17 (SARS-CoV-2-S-CO-AA), SEQ ID NO: 18 (SARS-CoV-2-S), SEQ ID NO: 19 (SARS-CoV-2-S-CO-AA-PP), SEQ ID NO: 20 (SARS-CoV-2-S-CO-AA-fneg-PP), and SEQ ID NO: 21 (SARS-CoV-2-S-CO-AA-fneg).

10 . A pharmaceutical composition comprising the recombinant measles viral vector of claim 1 and a pharmaceutically acceptable carrier.

11 . A method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus in a subject comprising administering to the subject (i) the recombinant measles viral vector of claim 1 or (ii) a pharmaceutical composition comprising the vector and a pharmaceutically acceptable carrier.

12 . A method for inducing an immune response against a coronavirus in a subject comprising administering to the subject (i) the recombinant measles viral vector of claim 1 or (ii) pharmaceutical composition comprising the vector and a pharmaceutically acceptable carrier.

13 . A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8 (S6), SEQ ID NO: 9 (S-CO), SEQ ID NO: 10 (S-CO-AA), SEQ ID NO: 11 (S), SEQ ID NO: 12 (S-CO-AA-PP), SEQ ID NO: 13 (S-CO-AA-fneg-PP), and SEQ ID NO: 14 (S-CO-AA-fneg).

14 . A nucleic acid encoding the polypeptide of claim 13 .

15 . A nucleic acid comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 (S6), SEQ ID NO: 2 (S-CO), SEQ ID NO: 3 (S-CO-AA), SEQ ID NO: 4 (SARS-CoV-2-S), SEQ ID NO: 5 (S-CO-AA-PP), SEQ ID NO: 6 (S-CO-AA-fneg-PP), and SEQ ID NO: 7 (S-CO-AA-fneg).

16 . A pharmaceutical composition comprising (i) the polypeptide of claim 13 , a nucleic acid encoding the polypeptide, or a recombinant vector comprising the nucleic acid and (ii) a pharmaceutically acceptable carrier.

17 . The recombinant measles viral vector of claim 1 , wherein the nucleic acid sequence encoding the SARS-COV-2 spike glycoprotein is SEQ ID NO: 3 (S-CO-AA).

18 . The recombinant measles viral vector of claim 1 , wherein the amino acid sequence of the SARS-COV-2 spike glycoprotein is SEQ ID NO: 10 (S-CO-AA).

19 . The recombinant measles viral vector of claim 1 , wherein the vector comprises a nucleic acid sequence of SEQ ID NO: 17 (SARS-COV-2-S-CO-AA).

20 . The recombinant measles viral vector of claim 1 , wherein the vector consists of a nucleic acid sequence of SEQ ID NO: 17 (SARS-COV-2-S-CO-AA).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2022
From: DUPREX, WILLIAM PAUL; TILSTON-LUNEL, NATASHA; NAMBULLI, SHAMKUMAR; MURPHY, LINDA J.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 062158/0650 →
Continuity (3)
Provisional Application 63071479 · Aug 28, 2020
Provisional Application 63039275 · Jun 15, 2020
Related Publication 20230272421A1 · Aug 31, 2023
References Cited (27)
US 11103576B1 · Duprex et al. · 2021 [cited by applicant]
US 11298417B2 · Duprex et al. · 2022 [cited by applicant]
CN 111218459A · 2020 [cited by applicant]
EP 3865180A1 · 2020 [cited by applicant]
WO WO9706270A1 · 1997 [cited by applicant]
WO WO9813501A2 · 1998 [cited by applicant]
WO WO2009032954A1 · 2009 [cited by applicant]
WO WO2021160850A1 · 2021 [cited by applicant]
“An Early Look at Vaccines for COVID-19”, [cited by applicant]
“UniProtKB—P0DTC2 (SPIKE-SARS2)”, published Apr. 22, 2020, retrieved on Nov. 8, 2021 from URL: uniprot.org/uniprot/P0DTC2, pp. 1-4. [cited by applicant]
Bankamp et al., “Genetic Characterization of Measles Vaccine Strains”, [cited by applicant]
Case et al., “Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2”, [cited by applicant]
De Swart et al., “Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection”, [cited by applicant]
Duckert et al., “Prediction of proprotein convertase cleavage sites”, [cited by applicant]
Hartman et al., “SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal trac… [cited by applicant]
Klimstra et al., “SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients”, [cited by applicant]
Liniger et al., “Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses,” [cited by applicant]
Malczyk et al., “A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform”, [cited by applicant]
Padron-Regalado, “Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains,” [cited by applicant]
Rennick et al., “Live-Attenuated Measles Virus Vaccine Targets Dendritic Cells and Macrophages in Muscle of Nonhuman Primates”, [cited by applicant]
Schneider-Schaulies et al., “Receptor usage and differential downregulation of CD46 by measles virus wild-type and vaccine strains”, [cited by applicant]
Sinitsyna et al., “Further-attenuated measles vaccine: Virus passages affect viral surface protein expression, immunogenicity and histopathology pattern in vivo”, [cited by applicant]
Takeda et al., “Measles Virus Attenuation Associated with Transcriptional Impediment and a Few Amino Acid Changes in the Polymerase and Accessory Proteins”, [cited by applicant]
U.S. Patent and Trademark Office, Invitation to Pay Additional Fees in International Patent Application No. PCT/US21/37339, dated Sep. 24, 2021. [cited by applicant]
U.S. Patent and Trademark Office, International Search Report in International Patent Application No. PCT/US2021/037339, dated Dec. 8, 2021. [cited by applicant]
U.S. Patent and Trademark Office, Written Opinion in International Patent Application No. PCT/US2021/037339, dated Dec. 8, 2021. [cited by applicant]
Wrapp et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”, Science, 367: 1260-1263 (2020). [cited by applicant]